289 related articles for article (PubMed ID: 19377918)
21. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
22. Spitz naevi may express components of the plasminogen activation system.
Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
[TBL] [Abstract][Full Text] [Related]
23. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Albo D; Berger DH; Rothman VL; Tuszynski GP
J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
[TBL] [Abstract][Full Text] [Related]
24. The role of the plasminogen activation system in angiogenesis and metastasis.
Rabbani SA; Mazar AP
Surg Oncol Clin N Am; 2001 Apr; 10(2):393-415, x. PubMed ID: 11382594
[TBL] [Abstract][Full Text] [Related]
25. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
27. Modulation of the plasminogen activator/plasmin system in rat liver regenerating by recruitment of oval cells.
Bisgaard HC; Santoni-Rugiu E; Nagy P; Thorgeirsson SS
Lab Invest; 1998 Mar; 78(3):237-46. PubMed ID: 9520937
[TBL] [Abstract][Full Text] [Related]
28. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
29. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
30. Urokinase-dependent cell surface proteolysis and cancer.
Blasi F; Verde P
Semin Cancer Biol; 1990 Apr; 1(2):117-26. PubMed ID: 2151734
[TBL] [Abstract][Full Text] [Related]
31. The role of the fibrinolytic system in corneal angiogenesis.
Vogten JM; Reijerkerk A; Meijers JC; Voest EE; Borel Rinkes IH; Gebbink MF
Angiogenesis; 2003; 6(4):311-6. PubMed ID: 15166500
[TBL] [Abstract][Full Text] [Related]
32. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
33. S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors.
Kwon M; MacLeod TJ; Zhang Y; Waisman DM
Front Biosci; 2005 Jan; 10():300-25. PubMed ID: 15574370
[TBL] [Abstract][Full Text] [Related]
34. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Almholt K; Nielsen BS; Frandsen TL; Brünner N; Danø K; Johnsen M
Oncogene; 2003 Jul; 22(28):4389-97. PubMed ID: 12853975
[TBL] [Abstract][Full Text] [Related]
35. Analysis of the invasion-metastasis mechanism in pancreatic cancer: involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells.
Tan X; Egami H; Nozawa F; Abe M; Baba H
Int J Oncol; 2006 Feb; 28(2):369-74. PubMed ID: 16391791
[TBL] [Abstract][Full Text] [Related]
36. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
Wells JM; Strickland S
J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
[TBL] [Abstract][Full Text] [Related]
37. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
[TBL] [Abstract][Full Text] [Related]
38. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
39. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.
Sharma MC; Sharma M
Curr Pharm Des; 2007; 13(35):3568-75. PubMed ID: 18220793
[TBL] [Abstract][Full Text] [Related]
40. Plasmin induces apoptosis of aortic valvular myofibroblasts.
Kochtebane N; Choqueux C; Passefort S; Nataf P; Messika-Zeitoun D; Bartagi A; Michel JB; Anglés-Cano E; Jacob MP
J Pathol; 2010 May; 221(1):37-48. PubMed ID: 20186923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
